Carlson Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Carlson Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-577,656	Closed	-$42.6M	–	327
2016 Q4	$42.6M	Buy	+577,656	New	+$47M	0.51%	58
2015 Q1	–	Sell	-82,700	Closed	-$9.91M	–	370
2014 Q4	$9.82M	Buy	+82,700	New	+$9.31M	0.1%	236

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Carlson Capital's VRTX Position: Q1 2017 in Review

Carlson Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2017, closing a stake of 577,656 shares — an estimated $42.6M sold.

Carlson Capital first reported a position in VRTX in Q4 2014 and held it in 2 quarters. The position peaked at $42.6M in Q4 2016. 522 funds tracked by Wall St. Rank hold VRTX as of Q1 2017.

Carlson Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Carlson Capital sold 577,656 Vertex Pharmaceuticals shares in Q1 2017, an estimated $42.6M.
Carlson Capital first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 2 quarters.
Carlson Capital's Vertex Pharmaceuticals position peaked at $42.6M in Q4 2016.
522 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2017.

Based on Carlson Capital's 13F filing for Q1 2017, filed 15 May 2017.